Search research articles
Contact Us
Filters
Showing results (441-450 of 636) with videos related to
Page
of 64
Sort By:
Circulation
|
November 15, 2016
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
W Schuyler Jones, Iris Baumgartner, William R Hiatt, et al.
Circulation
|
June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
The American Journal of Cardiology
|
March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
Heart (British Cardiac Society)
|
June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Kyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Journal of the American Heart Association
|
September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
Anthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
The American Journal of Cardiology
|
July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
JAMA
|
July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
John L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal
|
December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial
Patrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
Page
of 64
Search research articles
Search
Showing results (441-450 of 636) with videos related to
Sort By:
Page
of 64
Circulation
|
November 15, 2016
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
W Schuyler Jones, Iris Baumgartner, William R Hiatt, et al.
Circulation
|
June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
The American Journal of Cardiology
|
March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
Heart (British Cardiac Society)
|
June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Kyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Journal of the American Heart Association
|
September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
Anthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
The American Journal of Cardiology
|
July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
JAMA
|
July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
John L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal
|
December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial
Patrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
Page
of 64